Literature DB >> 30155949

Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer.

E Akgun1, C Caliskan1, O Bozbiyik1, T Yoldas1, M Sezak2, S Ozkok3, T Kose4, B Karabulut5, M Harman6, O Ozutemiz7.   

Abstract

BACKGROUND: The optimal timing of surgery following preoperative chemoradiotherapy (CRT) is controversial. This trial aimed to compare pathological complete response (pCR) rates obtained after an interval of 8 weeks or less versus more than 8 weeks.
METHODS: Patients with locally advanced rectal adenocarcinoma situated within 12 cm of the anal verge (T3-4 or N+ disease) were randomized to undergo total mesorectal excision (TME) within 8 weeks (classical interval, CI group) or after 8 weeks (long interval, LI group) following CRT.
RESULTS: Among the 327 included patients (CI 160, LI 167), the pCR rate was significantly higher in the LI group than in the CI group (10·0 versus 18·6 per cent; P = 0·027). The highest pCR rate (29 per cent) was observed between 10 and 11 weeks. There was statistically significant disease regression in the LI group, with better stage (P = 0·004) and T category (P = 0·001) than in the CI group. There was no significant difference in surgical quality (rates of tumour-positive margins, TME quality, anastomotic leakage and intraoperative perforation) between the groups. The overall morbidity rate was 22·5 per cent in the CI group and 19·8 per cent in the LI group (P = 0·307). Regression analysis including sex, age, clinical stage, tumour location, tumour differentiation, TME quality, concomitant chemotherapy and interval to surgery revealed no statistically significant predictors of pCR.
CONCLUSION: Disease regression and pCR rate are increased with an interval between CRT and surgery exceeding 8 weeks. Registration number: NCT03287843 (http://www.clinicaltrials.gov).
© 2018 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2018        PMID: 30155949     DOI: 10.1002/bjs.10984

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  16 in total

1.  Value of combined multiparametric MRI and FDG-PET/CT to identify well-responding rectal cancer patients before the start of neoadjuvant chemoradiation.

Authors:  Niels W Schurink; Lisa A Min; Maaike Berbee; Wouter van Elmpt; Joost J M van Griethuysen; Frans C H Bakers; Sander Roberti; Simon R van Kranen; Max J Lahaye; Monique Maas; Geerard L Beets; Regina G H Beets-Tan; Doenja M J Lambregts
Journal:  Eur Radiol       Date:  2020-02-07       Impact factor: 5.315

Review 2.  Organ Preservation in Rectal Cancer.

Authors:  Jonathan B Yuval; Hannah M Thompson; Julio Garcia-Aguilar
Journal:  J Gastrointest Surg       Date:  2020-04-20       Impact factor: 3.452

3.  Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial.

Authors:  Erhan Akgun; Cemil Caliskan; Osman Bozbiyik; Tayfun Yoldas; Basak Doganavsargil; Serdar Ozkok; Timur Kose; Bulent Karabulut; Nevra Elmas; Omer Ozutemiz
Journal:  BJS Open       Date:  2022-09-02

Review 4.  Endoscopic and MRI response evaluation following neoadjuvant treatment for rectal cancer: a pictorial review with matched MRI, endoscopic, and pathologic examples.

Authors:  Seth I Felder; Sebastian Feuerlein; Arthur Parsee; Iman Imanirad; Julian Sanchez; Sophie Dessureault; Richard Kim; Sarah Hoffe; Jessica Frakes; James Costello
Journal:  Abdom Radiol (NY)       Date:  2020-10-28

5.  Does a long interval between neoadjuvant chemoradiotherapy and surgery benefit the clinical outcomes of locally advanced rectal cancer? A systematic review and meta analyses.

Authors:  Miao Yu; Deng-Chao Wang; Sheng Li; Li-Yan Huang; Jian Wei
Journal:  Int J Colorectal Dis       Date:  2022-03-12       Impact factor: 2.571

Review 6.  Watch-and-wait Management for Rectal Cancer After Clinical Complete Response to Neoadjuvant Therapy.

Authors:  Jonathan B Yuval; Julio Garcia-Aguilar
Journal:  Adv Surg       Date:  2021-07-06

7.  Machine learning for predicting pathological complete response in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy.

Authors:  Chun-Ming Huang; Ming-Yii Huang; Ching-Wen Huang; Hsiang-Lin Tsai; Wei-Chih Su; Wei-Chiao Chang; Jaw-Yuan Wang; Hon-Yi Shi
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

8.  Gastrointestinal Malignancies and the COVID-19 Pandemic: Evidence-Based Triage to Surgery.

Authors:  Scott C Fligor; Sophie Wang; Benjamin G Allar; Savas T Tsikis; Ana Sofia Ore; Ashlyn E Whitlock; Rodrigo Calvillo-Ortiz; Kevin R Arndt; Sidhu P Gangadharan; Mark P Callery
Journal:  J Gastrointest Surg       Date:  2020-06-30       Impact factor: 3.452

9.  Temporal determinants of tumour response to neoadjuvant rectal radiotherapy.

Authors:  Kendrick Koo; Rachel Ward; Ryan L Smith; Jeremy Ruben; Peter W G Carne; Hany Elsaleh
Journal:  PLoS One       Date:  2021-06-30       Impact factor: 3.240

10.  Prevalence of nodal involvement in rectal cancer after chemoradiotherapy.

Authors:  H E Haak; G L Beets; K Peeters; P J Nelemans; V Valentini; C Rödel; L Kuo; F A Calvo; J Garcia-Aguilar; R Glynne-Jones; S Pucciarelli; J Suarez; G Theodoropoulos; S Biondo; D M J Lambregts; R G H Beets-Tan; M Maas
Journal:  Br J Surg       Date:  2021-10-23       Impact factor: 11.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.